Chamberlain RS - Search Results

1

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. Rao JB, et al. Among authors: chamberlain rs. J Immunol. 1996 May 1;156(9):3357-65. J Immunol. 1996. PMID: 8617961 Free PMC article.

2

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G. Moss B, et al. Adv Exp Med Biol. 1996;397:7-13. doi: 10.1007/978-1-4899-1382-1_2. Adv Exp Med Biol. 1996. PMID: 8718576 Free PMC article. Review.

3

Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.

Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Chamberlain RS, et al. Cancer Res. 1996 Jun 15;56(12):2832-6. Cancer Res. 1996. PMID: 8665522 Free PMC article.

4

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Carroll MW, et al. Among authors: chamberlain rs. Vaccine. 1997 Mar;15(4):387-94. doi: 10.1016/s0264-410x(96)00195-8. Vaccine. 1997. PMID: 9141209 Free PMC article.

5

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Irvine KR, et al. Among authors: chamberlain rs. J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601. doi: 10.1093/jnci/89.21.1595. J Natl Cancer Inst. 1997. PMID: 9362157

6

Route of immunization and the therapeutic impact of recombinant anticancer vaccines.

Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP. Irvine KR, et al. Among authors: chamberlain rs. J Natl Cancer Inst. 1997 Mar 5;89(5):390-2. doi: 10.1093/jnci/89.5.390. J Natl Cancer Inst. 1997. PMID: 9060962 Review. No abstract available.

7

Innovations and strategies for the development of anticancer vaccines.

Chamberlain RS, Kaufman H. Chamberlain RS, et al. Expert Opin Pharmacother. 2000 May;1(4):603-14. doi: 10.1517/14656566.1.4.603. Expert Opin Pharmacother. 2000. PMID: 11249505 Review.

8

Prospects for the therapeutic use of anticancer vaccines.

Chamberlain RS. Chamberlain RS. Drugs. 1999 Mar;57(3):309-25. doi: 10.2165/00003495-199957030-00004. Drugs. 1999. PMID: 10193685 Review.

9

Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment.

Chamberlain RS, Kaufman HL, Danforth DN. Chamberlain RS, et al. Am Surg. 1998 Dec;64(12):1204-11. Am Surg. 1998. PMID: 9843347

10

Carcinoid tumors of the extrahepatic bile duct. A rare cause of malignant biliary obstruction.

Chamberlain RS, Blumgart LH. Chamberlain RS, et al. Cancer. 1999 Nov 15;86(10):1959-65. Cancer. 1999. PMID: 10570419

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters